Americas Cancer Immunotherapy Market Research Report –Forecast till 2027

Americas Cancer Immunotherapy Market Research Report, By Cancer (Prostate, Colorectal, Head & Neck Cancer), Therapeutics (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Vaccines), End Users (Hospitals, Academic Institutes) - Forecast till 2027

ID: MRFR/Pharma/0149-HCR | February, 2021 | Region : Americas

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Therapeutics Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. The Americas Cancer Immunotherapy Market, by Cancer

6.1 Introduction

6.2 Lung Cancer

Market Estimates & Forecast, 2020-2027

6.3 Prostate Cancer

Market Estimates & Forecast, 2020-2027

6.4 Colorectal Cancer

Market Estimates & Forecast, 2020-2027

6.5 Head & Neck Cancer

Market Estimates & Forecast, 2020-2027

6.6 Others

Chapter 7. The Americas Cancer Immunotherapy Market, by Therapeutics

7.1 Introduction

7.2 Monoclonal Antibodies

Market Estimates & Forecast, 2020-2027

7.2.1 Naked Monoclonal Antibodies

7.2.1.1 Naked Monoclonal Antibodies

7.2.1.2 Alemtuzumab

7.2.1.3 Trastuzumab

7.2.1.4 Others

7.2.2 Conjugated Monoclonal Antibodies

7.2.3 Chemolabeled Antibodies

7.2.4 Bispecific Monoclonal Antibodies

7.2.5 Others

7.3 Immune Checkpoint Inhibitors

Market Estimates & Forecast, 2020-2027

7.3.1 PD-1 inhibitors

7.3.1.1 Pembrolizumab

7.3.1.2 Nivolumab

7.3.1.3 Others

7.3.2 PD-L1 inhibitors

7.3.2.1 Atezolizumab

7.3.2.2 Avelumab

7.3.2.3 Others

7.4 Vaccines

Market Estimates & Forecast, 2020-2027

7.5 Non-specific cancer immunotherapies and adjuvants

Market Estimates & Forecast, 2020-2027

7.5.1 Cytokines

7.5.2 Interleukins

7.5.3 Others

Chapter 8. The Americas Cancer Immunotherapy Market, by End Users

8.1 Introduction

8.2 Hospitals & Clinics

Market Estimates & Forecast, 2020-2027

8.3 Research Organization

Market Estimates & Forecast, 2020-2027

8.4 Retail Pharmacies

Market Estimates & Forecast, 2020-2027

8.5 Others

Chapter 9. The Americas Cancer Immunotherapy Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Amgen Inc.

11.1.1 Company Overview

11.1.2 Cancer Overview

11.1.3 Financials

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 AstraZeneca

11.2.1 Company Overview

11.2.2 Cancer Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 F. Hoffmann-La Roche Ltd.

11.3.1 Company Overview

11.3.2 Cancer Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Bayer AG

11.4.1 Company Overview

11.4.2 Cancer/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Bristol-Myers Squibb Company

11.5.1 Company Overview

11.5.2 Cancer Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Eli Lilly and Company

11.6.1 Company Overview

11.6.2 Cancer Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Merck & Co., Inc.

11.7.1 Overview

11.7.2 Cancer Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Pfizer Inc.

11.8.1 Overview

11.8.2 Cancer Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Novartis AG

11.9.1 Overview

11.9.2 Cancer Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of the Americas Cancer Immunotherapy Market

Chapter 13 Appendix

LIST OF TABLES

Table 1 The Americas Cancer Immunotherapy Industry Synopsis, 2020-2027

Table 2 The Americas Cancer Immunotherapy Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 The Americas Cancer Immunotherapy Market by Region, 2020-2027, (USD Million)

Table 4 The Americas Cancer Immunotherapy Market by Cancer, 2020-2027, (USD Million)

Table 5 The Americas Cancer Immunotherapy Market by Therapeutics, 2020-2027, (USD Million)

Table 6 The Americas Cancer Immunotherapy Market by End Users, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for the Americas Cancer Immunotherapy Market

Figure 3 Market Dynamics for the Americas Cancer Immunotherapy Market

Figure 4 The Americas Cancer Immunotherapy Market Share, by Cancer 2020

Figure 5 The Americas Cancer Immunotherapy Market Share, by Therapeutics 2020

Figure 6 The Americas Cancer Immunotherapy Market Share, by End Users, 2020

Figure 7 The Americas Cancer Immunotherapy Market Share, by Region, 2020

Figure 8 The Americas Cancer Immunotherapy Market: Company Share Analysis, 2020 (%)

Figure 9 Amgen Inc.: Key Financials

Figure 10 Amgen Inc.: Segmental Revenue

Figure 11 Amgen Inc.: Geographical Revenue

Figure 12 AstraZeneca: Cancer UK Ltd: Key Financials

Figure 13 AstraZeneca: Cancer UK Ltd: Segmental Revenue

Figure 14 AstraZeneca: Cancer UK Ltd: Geographical Revenue

Figure 15 F. Hoffmann-La Roche Ltd.: Key Financials

Figure 16 F. Hoffmann-La Roche Ltd.: Segmental Revenue

Figure 17 F. Hoffmann-La Roche Ltd.: Geographical Revenue

Figure 18 Bayer AG: Key Financials

Figure 19 Bayer AG: Segmental Revenue

Figure 20 Bayer AG: Geographical Revenue

Figure 21 Bristol-Myers Squibb Company: Key Financials

Figure 22 Bristol-Myers Squibb Company: Segmental Revenue

Figure 23 Bristol-Myers Squibb Company: Geographical Revenue

Figure 24 Eli Lilly and Company: Key Financials

Figure 25 Eli Lilly and Company: Segmental Revenue

Figure 26 Eli Lilly and Company: Geographical Revenue

Figure 27 Merck & Co., Inc.: Key Financials

Figure 28 Merck & Co., Inc.: Segmental Revenue

Figure 29 Merck & Co., Inc.: Geographical Revenue

Figure 30 Pfizer Inc.: Key Financials

Figure 31 Pfizer Inc.: Segmental Revenue

Figure 32 Pfizer Inc.: Geographical Revenue

Figure 33 Novartis AG: Key Financials

Figure 34 Novartis AG: Segmental Revenue

Figure 35 Novartis AG: Geographical Revenue

Cancer Immunotherapy Market Speak to Analyst Request a Free Sample